Navigation Links
Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
Date:10/6/2008

Vice President and Chief Medical Officer at Ironwood.

"These novel findings provide valuable insight into the possible role of cGMP in alleviating intestinal pain and may explain the reduction in intestinal pain observed in patients with IBS-C treated with linaclotide in our Phase 2b studies," said Mark Currie, Ph.D., Senior Vice President, R&D and Chief Scientific Officer at Ironwood.

About Linaclotide

Linaclotide is a first-in-class compound currently being evaluated for the treatment of IBS-C, chronic constipation (CC), and other gastrointestinal disorders. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide reduced abdominal pain and relieved constipation-the hallmarks of the condition-throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week study period. Linaclotide was well tolerated at all doses in both Phase 2b studies, with the most common adverse event being diarrhea. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. Ironwood retains exclusive rights to linaclotide outside of North America.

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Healthcare costs associated with IBS exceed $25 billion ann
'/>"/>

SOURCE Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015  The findings of ... raising disturbing questions about the company,s handling of its ... reports.  On September 2 nd , part one ... adverse events, including at least 27 fatalities, have been ... a confidential study commissioned by C.R. Bard in 2004 ...
(Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4q3mv2/investigation ) ... on China Olmesartan Market, 2010-2019" report to their ... successfully developed by Sankyo Pharmaceuticals Co., Ltd and was ... was approved by FDA to enter the American market ... drug in the world after it succeeded in the ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ... the "Investigation Report on China Tamsulosin Market, ... Compared with other a1- adrenergic receptor blockers, ... and lower risk of urinary tract infections and ... its debut in 1993 in Japan ...
Breaking Medicine Technology:IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3China Olmesartan Investigation Market Report 2010-2019 2China Tamsulosin Market Investigation Report 2015 2
... 2010 ViroPharma Incorporated (Nasdaq: VPHM ) ... Cinryze ® (C1 esterase inhibitor [human]) at the ... (WAO), December 5 through 8 in Dubai, UAE.   ... these data, which were first presented at the November ...
... Healthcare, a world-leading developer, manufacturer and marketer of innovative ... that in connection with a refinancing of its debt ... in combination with new senior secured credit facilities, it ... Senior Notes. The offering of the new notes will ...
Cached Medicine Technology:Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 2Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 3Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 4Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 5Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 6Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 7Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 8Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 9ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 2ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 3
(Date:9/3/2015)... ... September 03, 2015 , ... ... graduated compression garments. However, graduated compression garments are an effective solution for reducing ... specialist, Robyn Bjork, was recently sponsored by SIGVARIS for a unique ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... http://www.tamarahartley.com ) announces the release of her debut book, “Stop Wasting Your Time ... a Book Day (September 6), Hartley’s guide to overcoming life’s obstacles by taking ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... The ... mission control, the surface of a comet, the IceCube observatory at the South Pole, ... way. , The Fall Lecture Series for the world's foremost independently funded research ...
(Date:9/3/2015)... Kan. (PRWEB) , ... September 03, 2015 , ... ... dedicated exclusively to healthcare providers, has been retained to lead a national ... of the top executive search firms in the healthcare industry, B. E. Smith ...
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the world leader in ... its award-winning print and artwork inspection solutions, ScanProof and ArtProof at Packaging ... the Olympia London, booth #F33 , Be the first to get a sneak peek ...
Breaking Medicine News(10 mins):Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 3Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 2Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 4Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 5Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3
... 31 (HealthDay News) -- The white coats and medical scrubs ... study finds. Researchers in Israel swabbed nurses, and physicians, ... percent of the clothing items. The team, from ... collected from three parts -- sleeve ends, pockets and abdominal ...
... Scientists at The Scripps Research Institute have shown that a ... development and spread of cancerous tumors. Their work sheds new ... novel strategies for treating early-stage cancers. The study was ... Journal of Pathology . Scripps Research Professor James Quigley, ...
... 31 (HealthDay News) -- Older, heavier women tend to have ... new study suggests. The study included 52 women who ... symptoms. The women,s body fat percentage, waist circumference ... special skin monitor and electronic diary were used to track ...
... , WEDNESDAY, Aug. 31 (HealthDay News) -- Caring for a ... hard enough, but long-distance caregiving, which is becoming more common ... burdens. By 2012, an estimated 14 million Americans will ... names: "seagulls" and "pigeons." These terms refer to family ...
... in the late 1960s and early 1970s used marshmallows and ... gratification. If they held off on the temptation to eat ... of the children resisted, others didn,t. A newly published ... that these differences remain: Those better at delaying gratification as ...
... effectively detected concussions in collegiate athletes, according to a ... at the University of Pennsylvania. Concussed athletes scored an ... baseline scores in healthy controls on the timed test, ... cards and are scored on time and accuracy. This ...
Cached Medicine News:Health News:Dangerous Bacteria Hide Out in Nurses', Doctors' Uniforms 2Health News:Scripps Research scientists reveal how white blood cell promotes growth and spread of cancer 2Health News:Scripps Research scientists reveal how white blood cell promotes growth and spread of cancer 3Health News:Being Heavier May Mean Fewer Hot Flashes for Women Over 60 2Health News:For Many Americans, Caregiving a Long-Distance Burden 2Health News:For Many Americans, Caregiving a Long-Distance Burden 3Health News:40-year follow-up on marshmallow test points to biological basis for delayed gratification 2Health News:Visual test effective in diagnosing concussions in collegiate athletes 2
... comprised of Salicylic Acid Exfoliator 30% ... to be used by Physicians or ... designed for intense skin peeling and ... speed of skin correction. This kit ...
... Harvest, Wash & Transfer System is a ... fat transfer procedures simpler for the physician ... need for an office-based technique. LipiVage™ improves ... no longer a need to centrifuge, decant ...
... and Zyplast® injectable collagen implants have set ... facial lines, wrinkles and scars and in ... skins natural collagen, require minimal procedure time, ... one million people worldwide have been treated ...
... SCULPTRA™ is an injectable ... poly-L-lactic acid, a biocompatible, biodegradable, ... family. SCULPTRA is reconstituted prior ... of Sterile Water for Injection, ...
Medicine Products: